drugset / Trial / NCT05079022
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Phase 1/2
Unknown
50 enrolled
Peking University People's Hospital
Beijing CSCO-Allist Cancer Research Foundation · collabGuangzhou Burning Rock Medical Examination Institute Co., Ltd. · collabShanghai Allist Pharmaceutical Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the feasibility and effectiveness of ctDNA-MRD based adjuvant furmonertinib therapy in EGFR mutation-positive stage I lung adenocarcinoma patients after complete surgical resection.
Timeline
- Start
- 2021-10
- Primary completion
- 2023-03
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firmonertinib | Small molecule | 80 mg | Oral |